Emerging evidence demonstrates that G6PD overexpression diminishes regorafenib cytotoxicity in HCC (62), while METTL3-mediated activation of G6PD-dependent PPP flux drives oxaliplatin resistance (63). Here, G6PD is linked to hepatocellular carcinoma.